1 Reason This Biotech Stock Could Triple Before Year-End

When you think of GLP-1s and investing, the two large pharmaceutical companies benefiting most from this trend may first come to mind. First, there's Novo Nordisk, the first to bring GLP-1 weight loss drugs to market, with Ozempic and Wegovy. Second, there's Eli Lilly, beating Novo Nordisk at its own game, with its Zepbound GLP-1 treatment.Several other big pharma companies, like Pfizer, have their own injectable and oral-based GLP-1 candidates. The market incumbents are also working on orally administered candidates. But what if a lesser-known candidate, from a smaller biotech company, ultimately gives both Novo Nordisk and Lilly a run for their money?Let's take a closer look at Viking Therapeutics (NASDAQ: VKTX), a dark horse contender among GLP-1 stocks, and why this factor could be the stock's key to a threefold surge.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool